Hello! Welcome to Win-Win Chemical
english English    english 中文

Win-Win Fine Chemical Expert Heath Chemicals

Email: sales@win-winchemical.com

Hotline :0086-0577-64498589

Singapore develops first domestically produced oral drug for novel coronavirus
win-win Industry news
On January 14, the Experimental Drug Research and Development Center under the Agency for Science, Technology and Research (A*STAR) of Singapore recently developed a 3CL protease inhibitor, which will be used in the development of oral drugs for the new coronavirus in Singapore. In 2019, A*STAR established the Singapore Experimental Drug Research and Development Centre (EDDC) to strengthen the biomedical field in Singapore. Recently, the Experimental Drug Research and Development Center has successfully developed a 3CL protease inhibitor. The main protease in the new coronavirus is 3CL protease, and 3CL protease inhibitors prevent the virus from self-replication by inhibiting the expression of 3CL protease. This time, Singapore has developed a technology that can inhibit this protein, which is very effective against the new coronavirus and its variant strains. This is also the key technology used in Pfizer's new coronavirus oral medicine. On the 14th, China Genting Xinyao and Singapore's Experimental Drug Research and Development Center announced that they had reached a global license agreement to jointly develop and produce oral drugs for the new coronavirus. It is reported that the clinical trial plan of this new coronavirus oral drug will start in the second half of this year.
Read More...
CPHI China & P-MEC China 2021 extension announcement
win-win Industry news
Novel coronavirus pneumonia epidemic prevention and control situation is becoming more and more severe in recent years. In order to strictly implement the joint defense joint control mechanism of the State Council, in order to effectively protect the safety and health of participants, based on feedback from exhibitors, spectators and cooperative agencies, China has made many rounds of consultation and careful consideration. Shanghai Bohua International Exhibition Co., Ltd. has decided that the 21st world pharmaceutical raw materials China Exhibition and the 16th world pharmaceutical machinery, packaging equipment and materials China exhibition originally scheduled to be held from December 16 to 18, 2021 will be postponed to June 21-23, 2022, and the venue of the exhibition will remain unchanged (still Shanghai New International Expo Center). Although the offline exhibition has been postponed, the "VEC online exhibition" (VEC. Pharmasources. Com) of CPHI & p-mec China Exhibition held from November 18, 2021 to January 18, 2022 will continue as usual, continue to help exhibitors connect global buyers and play the role of brand exhibition exchange and cooperation platform. See you CPHI 2022!
Read More...
Pfizer's new oral drug PAXLOVID has applied for EUA, allowing patent-free imitations!
win-win Industry news
On November 16, local time, Pfizer's US official website showed that its company has submitted an emergency use authorization (EUA) for the new crown oral drug PAXLOVID to the FDA for the treatment of patients with mild to moderate COVID-19 who are at increased risk of hospitalization or death middle. PAXLOVID is an investigational SARS-CoV-2 protease inhibitor antiviral therapy. PF-07321332 is designed to block the activity of SARS-CoV-2-3CL protease, which is an enzyme required for coronavirus replication. Combining with low-dose ritonavir helps to slow down the metabolism or decomposition of PF-07321332, so that it stays active in the body at a higher concentration for a longer period of time to help fight the virus. At the same time, Pfizer announced on its official website that it and the Pharmaceutical Patent Pool (MPP) have signed a license agreement for COVID-19 oral antiviral therapy candidates to expand their accessibility in low- and middle-income countries. According to the terms of the general license agreement between Pfizer and MPP, qualified generic drug manufacturers authorized by MPP will be able to provide the drug to 95 countries, covering approximately 53% of the world's population. Including all low- and middle-income countries, as well as sub-Saharan middle- and high-income countries. In addition, it also includes countries that have transitioned from low-medium to high-medium status in the past five years.
Read More...
Diwali-Festival of Lights
win-win Industry news
On November 4, 2021, Diwali festival, also known as Wandeng Festival, Indian Lantern Festival and demon slaughtering Festival, is a festival for Hinduism, Sikhism and Jainism to "drive away darkness with light and overcome evil with good". Diwali festival lasts five days, and the third day is the climax of the festival. Fireworks and various festival lights will illuminate the dark night. May Diwali not only light up your house, but also your spirit, dream and hope. May God bless your health and happiness, and may all your undertakings be completed successfully. We wish you and your family a happy Lantern Festival!
Read More...
The energy "crisis" broke out! The price of chemical raw materials has risen collectively again!
win-win Industry news
Recently, an urgent document of the National Development and Reform Commission came out of the market. Regarding this urgent document, industry insiders said that the National Development and Reform Commission has begun to count coal production costs, which further reveals the recent emergency situation of China's coal. The recent continuous torrential rains have impacted the coal industry in Shanxi, a major coal province. 60 coal mines, 372 non-coal mines, and 14 hazardous chemical companies have ceased production throughout the province. This has caused the already tight supply of coal to be tested by the suspension of coal prices. It has soared recently. Since mid-to-late September, the global energy crisis has intensified. Power shortages in China, gas shortages in Europe, and oil shortages in the United Kingdom have intensified the contradiction between energy supply and demand, and energy prices have continued to soar. This has also had a greater impact on the chemical industry. Recently, the chemical market has been "bombed" by price increase letters from major global manufacturers. Wanhua Chemical, BASF, Dow, DuPont, and LANXESS have raised prices several times, driving the continuous price increase of downstream products. The prices of commonly used plastics such as EVA, PC, and PVC have repeatedly hit record highs, and the price increase schedule of some chemical products has been scheduled to February next year. The price increase letters from domestic chemical companies are also flooding in like snowflakes, making people too late to respond. On the whole, the root cause of the current round of global energy crisis is energy shortages caused by imbalances in supply and demand. Inventories are already at a low level, prompting the rise in prices of related commodities. According to industry insiders, the current global energy crisis is expected to last for several years. The soaring prices of oil, natural gas, coal and other commodities have triggered market concerns about inflation. The increase in costs in the upper and middle reaches will aggravate the supply chain crisis and further push up. Inflationary pressure in the chemical industry.
Read More...
On October 12, the 87th API China API Exhibition will meet you in Wuhan!
win-win Industry news
The 87th China International Pharmaceutical Raw Materials/Intermediates/Packaging/Equipment Fair (API China) and the 25th China International Pharmaceutical (Industry) Exhibition and Technology Exchange (CHINA-PHARM) will be held on October 12- On the 14th, it was held as scheduled at the Wuhan International Expo Center. The organizing committee of API China and CHINA-PHARM will work closely with Wuhan Municipal Government, Wuhan International Expo Center and other units to ensure the health and safety of the merchants. We will go all out to do business opportunities docking, exhibitor services, visitor invitations and other tasks, and join hands with all colleagues in the Chinese pharmaceutical industry to link the entire pharmaceutical industry chain, stimulate industry innovation and vitality, and jointly build a large platform for China's pharmaceutical internal circulation and a global pharmaceutical industry chain. Birthplace. See you in Wuhan on October 12!
Read More...
Page:1/ Total:5 First  Prev  Next  Last